Tolerability and toxicity profiles of antibody-drug conjugates for the treatment of malignant neoplasms: A meta-analysis of randomized clinical trials. This is an ASCO Meeting Abstract from the 2023 ...
In patients with advanced triple negative breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus pembrolizumab led to ...
TORONTO, ON / ACCESSWIRE / December 6, 2024 / ProteinQure, the leading company in computational design of peptide therapeutics, will be presenting compelling new data on the progress of their lead ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results